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Clinical outcomes and cost-effectiveness of brief guided 
parent-delivered cognitive behavioural therapy and 
solution-focused brief therapy for treatment of childhood 
anxiety disorders: a randomised controlled trial
Cathy Creswell*, Mara Violato*, Hannah Fairbanks, Elizabeth White, Monika Parkinson, Gemma Abitabile, Alessandro Leidi, Peter J Cooper
Summary
Background Half of all lifetime anxiety disorders emerge before age 12 years; however, access to evidence-based 
psychological therapies for affected children is poor. We aimed to compare the clinical outcomes and cost-effectiveness 
of two brief psychological treatments for children with anxiety referred to routine child mental health settings. We 
hypothesised that brief guided parent-delivered cognitive behavioural therapy (CBT) would be associated with better 
clinical outcomes than solution-focused brief therapy and would be cost-effective. 
Methods We did this randomised controlled trial at four National Health Service primary child and mental health 
services in Oxfordshire, UK. Children aged 5–12 years referred for anxiety difficulties were randomly allocated (1:1), 
via a secure online minimisation tool, to receive brief guided parent-delivered CBT or solution-focused brief therapy, 
with minimisation for age, sex, anxiety severity, and level of parental anxiety. The allocation sequence was not 
accessible to the researcher enrolling participants or to study assessors. Research staff who obtained outcome 
measurements were masked to group allocation and clinical staff who delivered the intervention did not measure 
outcomes. The primary outcome was recovery, on the basis of Clinical Global Impressions of Improvement (CGI-I). 
Parents recorded patient-level resource use. Quality-adjusted life-years (QALYs) for use in cost-utility analysis were 
derived from the Child Health Utility 9D. Assessments were done at baseline (before randomisation), after treatment 
(primary endpoint), and 6 months after treatment completion. We did analysis by intention to treat. This trial is 
registered with the ISCRTN registry, number ISRCTN07627865.
Findings Between March 23, 2012, and March 31, 2014, we randomly assigned 136 patients to receive brief guided 
parent-delivered CBT (n=68) or solution-focused brief therapy (n=68). At the primary endpoint assessment (June, 2012, 
to September, 2014), 40 (59%) children in the brief guided parent-delivered CBT group versus 47 (69%) children in 
the solution-focused brief therapy group had an improvement of much or very much in CGI-I score, with no 
significant differences between groups in either clinical (CGI-I: relative risk 1·01, 95% CI 0·86–1·19; p=0·95) or 
economic (QALY: mean difference 0·006, –0·009 to 0·02; p=0·42) outcome measures. However, brief guided parent-
delivered CBT was associated with lower costs (mean difference –£448; 95% CI –934 to 37; p=0·070) and, taking into 
account sampling uncertainty, was likely to represent a cost-effective use of resources compared with solution-focused 
brief therapy. No treatment-related or trial-related adverse events were reported in either group.
Interpretation Our findings show no evidence of clinical superiority of brief guided parent-delivered CBT. However, 
guided parent-delivered CBT is likely to be a cost-effective alternative to solution-focused brief therapy and might be 
considered as a first-line treatment for children with anxiety problems.
Funding National Institute for Health Research. 
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. 
Introduction
Anxiety disorders are among the most common mental 
health disorders and, because of their high prevalence, 
persistence, and associated impairment, have a greater 
economic burden than any other mental health condition.1 
Half of all lifetime cases emerge before age 12 years.2 
Effective treatments for anxiety disorders in children 
exist;3 however, fewer than a third of children with an 
anxiety disorder access professional help.4 Both parental 
preferences5 and treatment side-effect profiles6 indicate 
the use of psychological treatments as the first-line 
treatment, yet evidence-based psychological treatments 
are typically lengthy (eg, 14–16 h-long sessions)4 and 
studies have mainly been done in specialist settings. Cost-
effective psychological treatments suitable for routine 
clinical practice are needed.
Systematic evaluations of psychological interventions 
for childhood anxiety disorders have been limited to 
cognitive behavioural therapy (CBT).7 Although good 
evidence exists for the efficacy of CBT compared with 
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waiting-list controls, few studies have compared this 
therapy with an active comparator and, when this has 
been done, the comparator has most commonly been an 
attention control condition rather than an established 
treatment.3 CBT can be effectively delivered in a brief 
form, whereby parents are supported in applying CBT 
principles. This approach is superior to a waiting-list 
comparison,8 with similar outcomes to CBT delivered in 
a more intensive traditional form.9 Indeed, brief guided 
parent-delivered CBT might be a cost-effective first-line 
treatment for childhood anxiety disorders. However, 
whether this therapy would be superior to a credible, 
alternative, brief psychological treatment remains 
unclear. We therefore aimed to compare the effectiveness 
and cost-effectiveness of two brief psychological 
treatments for childhood anxiety. We selected solution-
focused brief therapy as the usual-care comparator 
because it is widely used in National Health Service 
(NHS) mental health settings, in which only a few 
sessions can be provided. Although this approach has 
not been evaluated with children with anxiety disorders 
specifically, our consultations revealed that it was the 
most commonly used approach for working with 
children with a range of difficulties, including anxiety, in 
the NHS services participating in this trial. 
Methods 
Study design and participants
We did this randomised controlled trial in children 
referred to four NHS primary child and adolescent 
mental health services in Oxfordshire, UK. Families were 
invited to participate if the child was aged 5–12 years with 
anxiety associated with clinical impairment as the 
primary presenting problem. We excluded children 
prescribed psychotropic medication, and parents or 
children with little understanding of English or with 
physical or intellectual impairment (including autism 
spectrum disorder) that would interfere with their ability 
Research in context
Evidence before this study
Anxiety disorders are among the most common mental 
health disorders. Half of all lifetime cases emerge before age 
12 years, affecting a substantial proportion of children 
worldwide. Good evidence exists to show that cognitive 
behavioural therapy (CBT) is an effective treatment for 
childhood anxiety, compared with waiting-list controls, with 
recovery rates around 60%. However, how CBT compares 
with other psychological therapies that are used in child 
mental health services remains unclear. Furthermore, most 
trials of CBT involve at least nine face-to-face treatment 
sessions, although this is not always practical in routine 
health settings in which resources are often scarce. We 
searched PsycINFO and MEDLINE from Jan 1, 2000, to 
April 1, 2016, with the search terms “anxi*”; “child”, 
“adolescent”, “paediatric”, “pediatric”, “youth”; “treatment”, 
“intervention”, “therapy”, “psychotherapy”; “bibliotherapy”, 
“computer*”, “technology”; and “randomi* controlled trial”, 
“clinical trial’ to identify brief psychological interventions for 
childhood anxiety disorders. The most frequently evaluated 
brief treatment for childhood anxiety disorders was guided 
parent-delivered CBT (four studies) in which parents are 
supported by a therapist in working through a book that 
provides strategies to help them implement CBT strategies in 
their child’s day-to-day life; however, none of the studies 
compared a brief psychological intervention with a credible 
control treatment, and none included an economic analysis.
Added value of this study
In this study, we compared the effect of two brief 
psychological interventions on both clinical and economic 
outcomes in children referred for problems with anxiety. 
40 (59%) children in the brief guided parent-delivered CBT 
group versus 47 (69%) children in the solution-focused brief 
therapy group had an improvement of much or very much in 
Clinical Global Impression of Improvement score at the 
assessment after treatment, and 45 (66%) versus 49 (72%) 
children had an improvement at the 6 month follow-up 
assessment, with no significant differences between groups 
across both timepoints (relative risk 1·01, 95% CI 0·86–1·19; 
p=0·95). We did not find a significant difference in costs of 
providing the two therapies, both delivered with 5 h of 
therapist contact; however, when we considered the joint 
distribution of incremental mean costs and effects, brief 
guided parent-delivered CBT was likely to be cost-effective 
compared with solution-focused brief therapy.
Implications of all the available evidence
To our knowledge, this randomised controlled trial is the first 
to provide data for the outcomes of brief guided 
parent-delivered CBT compared with solution-focused brief 
therapy for childhood anxiety disorders in routine clinical 
practice. Although previous studies have shown that guided 
parent-delivered CBT is an effective treatment for childhood 
anxiety disorders compared with waiting-list controls, our 
findings show that it is no better than an alternative brief 
psychological treatment, solution-focused brief therapy, in 
terms of children’s outcomes. Nonetheless, brief guided 
parent-delivered CBT might be a more cost-effective 
approach, building on previous studies that support its use as 
a low-intensity intervention to improve access to evidence-
based treatments for childhood anxiety. Further studies are 
needed to examine how effective psychological treatments 
can be delivered at reduced costs without negatively affecting 
clinical outcomes and to establish the longer-term 
cost-benefits of intervention for children with these common, 
debilitating, and often chronic difficulties.
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to participate in assessments or treatment. Meeting 
diagnostic criteria for an anxiety disorder was not an 
inclusion criterion because we wanted to include all 
children referred for anxiety related problems.
The study was approved by the University of Reading 
(reference 12/02) and Oxford Health NHS Foundation 
Trust (reference 11/SC/0472) research ethics committees. 
Parents provided written consent and children written 
assent before randomisation.
Randomisation and masking
Baseline assessments were done as part of routine clinical 
assessments before randomisation. The researcher who 
enrolled eligible participants then informed the study 
clinical supervisor (MP), who was independent of the 
recruitment process, who allocated children to trial 
groups, informed families, and allocated clinicians. 
Participants were randomly allocated (1:1), via a secure 
online minimisation tool developed by a researcher with 
no clinical involvement in the trial, to receive brief guided 
parent-delivered CBT or solution-focused brief therapy. 
The minimisation tool was developed to balance the 
two treatment groups for child age (in months), sex (male 
vs female), anxiety severity (Anxiety Disorders Interview 
Schedule Clinician Severity Rating; mild, moderate, 
severe), and level of parental anxiety (measured with the 
anxiety subscale of the 21 item Depression Anxiety and 
Stress Scale; mild, moderate, severe).10 The minimisation 
algorithm operated on the basis of 80% minimisation and 
20% random allocation. However, the first nine patients 
were all allocated randomly to ensure that the algorithm 
was not predictable to research staff.
To ensure appropriate allocation concealment, the 
allocation sequence was retained on the secure online 
minimisation program, which was only accessible to the 
principal investigator (CC) and the clinical supervisor 
(MP) who allocated participants to clinicians. The 
allocation sequence was not accessible to the researcher 
enrolling participants or to study assessors. The trial 
adhered to procedures to maintain separation between 
research staff who measured outcomes and clinical staff 
who delivered the intervention. Research staff who 
obtained outcome measurements were masked to group 
allocation and clinical staff who delivered the intervention 
did not measure outcomes.
Procedures
Families in both treatment groups received roughly 5 h 
of treatment, which was audio recorded to allow for 
checks of treatment adherence.
For brief guided parent-delivered CBT, as in previous 
studies,8,11 parents were given a self-help book12 and received 
up to eight weekly sessions of therapist supported brief 
guided parent-delivered CBT (5 h total contact). Four of 
these sessions were done face to face (about 45 min) and 
four were brief telephone reviews (about 15 min). The 
treatment focused on psychoeducation about childhood 
anxiety, identification and testing of anxious thoughts, 
graded exposure, and problem solving. Parents completed 
homework tasks between sessions, both independently 
and with their child. The therapists followed a treatment 
manual specific to this programme,13 which instructed 
them in how to support and encourage parents to work 
through the self-help book, rehearse skills, and solve any 
problems that arose.
Solution-focused brief therapy is a form of counselling 
that is future-focused and works with the strengths and 
resources of the individual to build solutions. The 
delivery format was based on usual practice within the 
participating services and consultations with an expert 
adviser from BRIEF (a leading international centre 
for solution-focused brief therapy training). Solution-
focused brief therapy comprised an initial face-to-face 
session with the parent and child to initiate treatment 
(60 min), four face-to-face sessions of solution-focused 
brief therapy with the child (four 45 min sessions), and a 
final session with the child and parent (60 min; 5 h total 
contact). Therapists followed a manualised approach that 
was adapted from a solution-focused practice manual, 
and consistent with the European Brief Therapy 
Association practice definition.14
Therapists were primary mental health workers 
employed within participating services with a range 
of back grounds, including health visiting, nursing, 
occupational therapy, social and youth work, and clinical 
psychology and psychology graduates; and with varying 
degrees of experience in working with parents and 
children (none to several years). Therapists received 
2 days of training in each treatment approach and 
fortnightly supervision throughout the trial. They were 
each allocated to deliver one treatment for the first half of 
the trial and the other treatment for the second half (with 
training before each treatment phase). Participants were 
allocated to receive treatment with the next available 
clinician who was assigned to the appropriate treatment 
within their locality team.
Outcomes
Assessment points were at baseline (before randomisation), 
after treatment (primary endpoint), and 6 months after 
treatment completion. Assessments were done in par-
ticipants’ homes (unless this was not possible or wanted, 
and an alternative venue [eg, school] was organised).
The primary outcome was clinician-rated recovery. The 
primary indicator of recovery was an improvement of 
much or very much in the child’s difficulties, on the basis 
of Clinical Global Impression of Improvement (CGI-I),15 
as determined by independent assessors. The CGI-I was 
established on the basis of the parent report and child 
report on the Anxiety Disorders Interview Schedule, 
child and parent version (ADIS-c/p),16 which assesses the 
frequency and severity of symptoms of DSM-IV anxiety 
disorders and associated interference. The ADIS-c/p has 
not been validated in a child-report form in children 
For more about BRIEF see 
https://www.brief.org.uk
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younger than 7 years; therefore, parents of children aged 
5–6 years completed the full ADIS and children were 
administered a brief version.
Secondary outcome measures were clinical severity 
ratings from the ADIS-c/p, and parent-report and 
child-report questionnaires of anxiety symptoms and 
interference. Symptoms of anxiety were assessed among 
children aged 7 years and older with the Spence Children’s 
Anxiety Scale-child and parent version (SCAS-c/p)17— 
a parent-report and child-report questionnaire validated 
with children of this age.18,19 All children completed the 
Koala Fear Questionnaire, which has been validated in 
children aged 4 years and older.20 Interference associated 
with anxiety within school, social, and home and family 
domains was assessed with the Child Anxiety Impact 
Scales, child and parent version (CAIS-c/p).21,22 The 
CAIS-c was used in children from age 7 years; we removed 
two items about dating that are not typically applicable at 
this age. For children who met diagnostic criteria for a 
current anxiety disorder, we additionally examined the 
dichotomous outcomes of recovery from primary anxiety 
disorder and recovery from all anxiety disorders, on the 
basis of the ADIS-c/p.
We adopted a societal perspective in assessment of 
resource use and costs. Treatment-related health care 
and other patient-level resource-use data were collected 
over three separate time periods (3 months before 
baseline assessment, baseline to after treatment, after 
treatment to 6 month follow-up) on a modified Client 
Service Receipt Inventory form23 by use of parent-report 
patient-health diaries. These data included all health, 
social care, non-NHS (eg, educational) cost-generating 
services, and lost leisure and productivity time estimates 
for parents.
We assessed child quality of life with the Child Health 
Utility 9D (CHU-9D)24—a paediatric generic preference-
based measure of health-related quality of life, completed 
by children and their main caregiver. Preference weights 
for the CHU-9D valuation were obtained from a UK 
general population sample.24 We used the Euroqol-5D-
Youth version25 in sensitivity analyses. Both measures 
allow for calculation of quality-adjusted life-years (QALYs) 
for use in cost-utility analysis.
Statistical analysis
Data collection was in pen and paper form and data were 
initially entered in to SPSS datasheets (version 22).
Probable outcomes for CGI-I were not available for 
solution-focused brief therapy for childhood anxiety, so 
the study was powered on the basis of two considerations: 
(1) a two-thirds difference in the proportion of recovered 
children, because this outcome could be considered 
justification for service changes required to adopt a new 
approach; and (2) a meta-analysis of mixed outcomes of 
solution-focused brief therapy26 reported an effect size 
of 0·26 for internalising problems (including anxiety) 
compared with 0·52 in feasibility work using guided 
parent-delivered CBT.11 A sample size of 136 would 
provide 80% power to detect either difference at a 
two-sided 5% significance level.
A full data analysis plan was produced by the statistician 
(HF) and principal investigator (CC) before database lock. 
Analyses were done on a complete case basis on 
unmasked data. We did analyses by intention to treat. For 
primary and secondary analyses, mixed models were 
fitted to each outcome including the fixed effects of 
treatment; timepoint (categorical: before, after, 6 months); 
Figure 1: Trial profile
GPD-CBT=guided parent-delivered cognitive behavioural therapy. SFBT=solution-focused brief therapy. 
ASD=autism spectrum disorder. *Oppositional defiant disorder (n=5), dysthymia (n=1), obsessive compulsive 
disorder (n=3), major depressive disorder (n=2), post-traumatic stress disorder (n=3), autistic spectrum disorder 
(n=3), and tic disorder (n=1). †One child assigned to solution-focused brief therapy received brief guided 
parent-delivered CBT in error; as such, the analysis was repeated on the treatment-received population (n=69 in 
the GPD-CBT group and n=67 in the SFBT group). ‡Completed 6 month follow-up assessment.
68 allocated to the GPD-CBT group†
13 lost to follow-up
 4 did not complete treatment and 
  were not further contactable
 2 did not receive treatment (not 
  contactable or changed mind 
  about wanting help)
 3 families withdrew because 
  wanted different treatment
 2 families withdrew to seek support 
  relating to ASD and adoption
 2 refused assessment for medical 
  reasons‡
55 completed post-treatment follow-up 
1 refused second follow-up
56 completed 6 month follow-up 
68 allocated to the SFBT group†
3 lost to follow-up
 1 did not receive treatment (not 
  contactable or changed mind 
  about wanting help)
 1 family withdrew because wanted 
  different treatment
 1 not contactable for assessment‡ 
 
65 completed post-treatment follow-up 
4 refused second follow-up
62 completed 6 month follow-up 
275 children referred for anxiety problems
28 not assessed
 11 no longer wanted help with anxiety
 15 had accessed help elsewhere
 2 not contactable
247 assessed for eligibility
24 ineligible
 18 primary problem was not anxiety 
  with clinical impairment*
 5 no significant concerns about child
 1 too old by time of assessment
87 eligible but consent not given
136 randomly assigned
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treatment by timepoint interaction; child’s sex, age, and 
primary disorder type; and parental anxiety level (at the 
minimisation stage). For the primary analysis (CGI-I), a 
log-binomial mixed model was fitted including the 
additional fixed effect baseline severity of the child’s 
primary anxiety disorder (ADIS clinical severity ratings). 
Linear mixed models were fitted for the continuous 
secondary analyses, which also included the fixed effect 
baseline total score for the endpoint being analysed. The 
baseline severity of the child’s primary anxiety disorder 
was not included in the analysis because of its high 
correlation with the baseline total score of the endpoints 
being analysed. Additional analyses were done to model 
the binary outcomes: free from primary diagnosis, and 
free from all anxiety diagnoses. The same underlying 
model as the primary CGI-I analysis was fitted to these 
endpoints. Repeated measurements were taken into 
account by allowing measurements taken on the same 
child to be correlated in all models. Relative risks or 
differences were estimated to compare categorical fixed 
effects. Parameter estimates were obtained for continuous 
fixed effects. We calculated 95% CIs for all estimates.
Lack of convergence in the generalised mixed models 
for CGI-I, free from primary, and free from all 
diagnoses resulted in the fixed effects of child’s type of 
primary disorder, baseline severity of the child’s 
primary anxiety disorder, and parental anxiety level, 
being removed from these models. The fixed effect of 
sex was also removed from the model of free from 
primary diagnosis. Analyses of clinical outcomes were 
done with SAS (version 9.3).
For the base-case economic evaluation, we adopted a 
cost-utility analysis framework to assess the cost-
effectiveness of brief guided parent-delivered CBT 
compared with solution-focused brief therapy from a 
societal perspective. We followed current best-practice 
methods for conducting and reporting economic 
evaluation alongside trials.27 Costs were expressed in 
pounds sterling (£) in 2013–14 prices. In view of the 
short timeframe of the trial and follow-up, discounting 
was not applied to costs or effects. An intention-to-treat 
approach was adopted in the base-case analysis. 
Missing data for resource use and health outcomes 
were imputed by use of mean imputation for missing 
values deemed highly deterministic (eg, face-to-face 
therapists contact), and multiple imputation for 
other resources (eg, use of medications), under the 
assumption of missing at random.28 For each trial 
participant, all components of treatment costs, stratified 
by category of resource use, and other wider societal 
costs (educational services, travel costs, time off school 
or, for the main caregiver, work) were computed by 
multiplying units of resource use by their unit costs 
(appendix). These values were then summed to obtain a 
total cost for each patient. 
A deviation from the original protocol was that days off 
school were considered a consequence rather than an 
GPD-CBT (n=68) SFBT (n=68)
Age (months) 111·31 (21·93) 109·74 (26·76)
Sex
Female 36 (53%) 36 (53%)
Male 32 (47%) 32 (47%)
Ethnic group
White British 62 (91%) 65 (96%)
Other* 6 (9%) 3 (4%)
Two-parent household 60 (88%) 56 (82%)
Employment status of participating parent
Unemployed 18 (26%) 15 (22%)
Part-time work 38 (56%) 36 (53%)
Full-time work 11 (16%) 15 (22%)
Employed–unspecified 0 2 (3%)
Missing 1 (1%) 0
Household income (£)
<10 000 5 (7%) 6 (9%)
10–15 000 5 (7%) 3 (4%)
15–20 000 8 (12%) 6 (9%)
20–30 000 8 (12%) 12 (18%)
30–40 000 8 (12%) 12 (18%)
40–50 000 12 (17%) 9 (13%)
>50 000 20 (30%) 18 (26%)
Missing 2 (3%) 2 (3%)
Education level of participating parent
Higher education 27 (40%) 22 (32%)
Socioeconomic status (highest of parent or partner)
Associate professional 
or technical
42 (62%) 40 (59%)
Anxiety level of participating parent (DASS-A)
Normal (0–3) 51 (75%) 50 (74%)
Borderline (4–7) 13 (19%) 13 (19%)
High (≥8) 4 (6%) 5 (7%)
Primary diagnosis of child anxiety disorder
Separation anxiety disorder 10 (15%) 13 (19%)
Social anxiety disorder 6 (9%) 8 (12%)
Generalised anxiety disorder 33 (49%) 36 (53%)
Specific phobia 17 (25%) 10 (15%)
Other† 2 (3%) 1 (1%)
ADIS-c/p clinical severity rating
Mild (3) 6 (9%) 8 (12%)
Moderate (4–5) 31 (46%) 32 (47%)
Severe (6–8) 31 (46%) 41 (28%)
Data are mean (SD) or n (%), unless otherwise stated. GPD-CBT=guided 
parent-delivered-cognitive behavioural therapy. SFBT=solution-focused brief 
therapy. DASS-A=Depression Anxiety and Stress Scales-Anxiety subscale. 
ADIS-c/p=Anxiety Disorders Interview Schedule for DSM-IV-child and parent 
version. *GPD-CBT: white Irish (n=1), any other white background (n=1), white 
and black Caribbean (n=3), and Pakistani (n=1); SFBT: white and black African 
(n=1), any other mixed background (n=1), Caribbean (n=1). †Panic disorder with 
or without agoraphobia or anxiety disorder not otherwise specified.
Table 1: Baseline demographic and clinical characteristics
See Online for appendix
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outcome and were included in the costs part of the 
economic analysis, in line with relevant economic 
literature. This decision was made in April, 2015, and 
was orally agreed with the principal investigator (CC). 
Independent members of the trial steering committee 
did not consult on this deviation as it was not considered 
to be substantial by the trial management group (and 
there was no  independent health economic expertise on 
the trial steering committee).29
Effects were identified and measured using QALYs, 
derived from the CHU-9D child report in the base-case 
analysis. Incremental mean costs and effects, and the 
associated 95% CIs, were estimated comparing the 
two intervention groups. Incremental cost-effectiveness 
ratios were estimated and reported where relevant. 
Uncertainty in the cost-effectiveness results was 
analysed by use of cost-effectiveness acceptability 
curves over a range of potential threshold values that 
the health system might be willing to pay for an 
additional QALY gained.30 Furthermore, we did ten 
sensitivity analyses to examine robustness of the base-
case analysis results. We additionally did a cost-
effectiveness analysis using the main clinical outcome 
of CGI-I.
Analyses of economic outcomes were done with STATA 
(version 13.1). This trial was registered with the ISCRTN 
registry, number ISRCTN07627865, on March 13, 2012.
Role of the funding source
The funder of the study reviewed the study proposal, 
awarded funding, and monitored the conduct of the 
study. The funders had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
Between March 23, 2012, and March 31, 2014, we randomly 
assigned 136 children to receive brief guided parent-
delivered CBT (n=68) or solution-focused brief therapy 
GPD-CBT (n=68) SFBT (n=68)
Dichotomous measures of outcome
CGI-I much or very much improved
After treatment 40 (59%) 47 (69%)
6 month follow-up 45 (66%) 49 (72%)
Free of primary anxiety disorder diagnosis
After treatment 33 (50%) 40 (59%)
6 month follow-up 47 (69%) 46 (68%)
Free of all anxiety disorder diagnoses
After treatment 25 (37%) 30 (44%)
6 month follow-up 34 (50% 35 (51%)
Continuous measures of outcome
ADIS-c/p clinical severity rating of primary diagnosis*
Baseline 5·10 (1·08); n=68 5·13 (1·02); n=68
After treatment 2·60 (2·00); n=55 2·77 (1·94); n=65
6 month follow-up 1·88 (1·90); n=56 1·89 (1·96); n=62
SCAS-c*
Baseline 38·61 (20·31); n=54 34·15 (20·06); n=60
After treatment 31·49 (24·09); n=45 24·36 (18·28); n=59
6 month follow-up 23·77 (18·96); n=44 19·55 (17·08); n=55
SCAS-p*
Baseline 35·41 (17·55); n=66 32·56 (13·54); n=66
After treatment 24·76 (12·88); n=51 24·44 (13·61); n=62
6 month follow-up 22·41 (11·58); n=51 23.05 (14.67); n=58
CAIS-c (25 items)*
Baseline 15·95 (11·89); n=55 16·85 (11·44); n=62
After treatment 10·55 (12·02); n=44 10·39 (9·80); n=59
6 month follow-up 9·68 (13·56); n=41 7·88 (7·90); n=52
CAIS-p (25 items)*
Baseline 20·43 (12·24); n=64 19·90 (11·47); n=62
After treatment 13·59 (12·41); n=51 12·04 (9·91); n=57
6 month follow-up 10·84 (11·79); n=49 12·27 (10·93); n=55
(Table 2 continues in next column)
GPD-CBT (n=68) SFBT (n=68)
(Continued from previous column)
KFQ-c*
Baseline 59·93 (11·33); n=68 58·68 (12·04); n=68
After treatment 52·96 (14·22); n=50 51·56 (13·17); n=62
6 month follow-up 50·23 (11·75); n=47 47·40 (12·94); n=58
CHU-9D-c†
Baseline 0·87 (0·09); n=64 0·88 (0·09); n=65
After treatment 0·90 (0·10); n=49 0·90 (0·09); n=59
6 month follow-up 0·91 (0·08); n=47 0·91 (0·08); n=55
CHU-9D-p†
Baseline 0·85 (0·10); n=46 0·89 (0·07); n=54
After treatment 0·92 (0·07); n=53 0·92 (0·07); n=53
6 month follow-up 0·93 (0·07); n=48 0·92 (0·07); n=56
EQ-5D-Y-c†
Baseline 0·82 (0·15); n=63 0·80 ( 0·20); n=67
After treatment 0·88 (0·21); n=48 0·86 (0·21); n=61
6 month follow-up 0·87 (0·19); n=47 0·91 (0·16); n=57
Data are n (%) or mean (SD); n. GPD-CBT=guided parent-delivered-cognitive 
behavioural therapy. SFBT=solution-focused brief therapy. CGI-I=Clinician Global 
Impression-Improvement. ADIS-c/p=Anxiety Disorders Interview Schedule for 
DSM-IV child and parent version. SCAS-c=Spence Children’s Anxiety Scale-child 
report. SCAS-p=Spence Child Anxiety Scale-parent report. CAIS-c=Child Anxiety 
Impact Scale-child report. CAIS-p=Child Anxiety Impact Scale-parent report. 
KFQ-c=Koala Fear Questionnaire-child report. CHU-9D-c=Child Health 
Utility-9D-child report. CHU-9D-p=Child Health Utility-9D-parent report. 
EQ-5D-Y=EuroQol-5D-Youth version-child report. *A higher score indicates 
higher symptoms or severity. †A higher score indicates higher quality of life.
Table 2: Primary, secondary, and economic outcome measures
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(n=68; figure 1). One child assigned to the solution-
focused brief therapy group received brief guided parent-
delivered CBT in error; as such, the analysis was repeated 
on the treatment-received population (n=69 in the brief 
guided parent-delivered CBT group and n=67 in the 
solution-focused brief therapy group), with no changes 
in the overall conclusions.The timing of the assess ments 
before randomisation, after treatment (June, 2012, 
to September, 2014), and 6 months after treatment 
completion (November, 2012, to December, 2014) did not 
differ significantly between groups (appendix). Baseline 
characteristics were similar between groups (table 1). 
122 (90%) participants met criteria for a diagnosis of 
current anxiety disorder, despite this not being an 
inclusion criterion.
Before delivering treatment, 17 (90%) of 19 therapists 
reported that they used solution-focused brief therapy 
and 19 (100%) used CBT at least sometimes. Therapists 
varied in whom they typically worked with in their 
routine practice with children with anxiety problems 
(work with children, parents, or both: sometimes, three 
[17%], five [28%], two [11%]; frequently, eight [44%], 
nine [50%], eleven [61%]; or always, seven [39%], 
four [22%], five [28%], respectively [data missing for 
one clinician]). Recordings of a random sample of 
52 treatment sessions were rated for treatment 
adherence by raters masked to treatment group. 
Session content was clearly differentiated, with brief 
guided parent-delivered CBT having more brief guided 
parent-delivered CBT-allowable content than solution-
focused brief therapy (t[50]=16·88; p<0·0001) and 
solution-focused brief therapy having more solution-
focused brief therapy-allowable content than brief 
guided parent-delivered CBT (t[50]=22·31; p<0·0001).
Inter-rater reliability was high for the primary outcome 
of CGI-I (mean κ=0·92, 95% CI 0·86–1·0). 40 (59%) 
children in the brief guided parent-delivered CBT group 
versus 47 (69%) children in the solution-focused brief 
therapy group had an improvement of much or very 
much in CGI-I score at the assessment after treatment, 
and 45 (66%) versus 49 (72%) children had an 
improvement at the 6 month follow-up assessment 
(table 2), with no significant differences between groups 
across both timepoints (relative risk 1·01, 95% CI 
0·86–1·19; p=0·95; table 3).
Inter-rater reliability was good for both anxiety disorder 
diagnoses (κ=0·86, 95% CI 0·75–0·98) and clinical 
severity ratings (intraclass correlation coefficient 0·91, 
95% CI 0·79–1·0) from the ADIS-c/p. No secondary 
outcome differed significantly between groups; however, 
all secondary endpoints except for CAIS-c reduced 
significantly over time (tables 2, 4). No treatment-related 
or trial-related adverse events were reported in either 
group.
QALYs gained over the trial period did not differ 
significantly between groups in the base-case analysis 
(mean difference 0·006, 95% CI –0·009 to 0·02; 
p=0·42). The mean societal cost for children was £1494 
(SD 1107·79) for patients in the brief guided parent-
delivered CBT and £1942 (1590·91) for patients in the 
solution-focused brief therapy group (mean difference 
–£448, 95% CI –934 to 37; p=0·070). The main drivers 
of the lower cost of the CBT intervention were treatment 
costs (mean difference –£133, 95% CI –204 to –63; 
p<0·0001), and time off school, work, or leisure time 
for children and parents (–£200, –386 to –13; p=0·036). 
In particular, despite the fact that both treatments 
lasted a similar time, cost savings occurred in the 
therapists’ travel costs associated with the treatment 
delivery, both in terms of opportunity cost of their time 
(ie, time that they could have spent in other activities) 
and mileage cost, and time spent in administrative 
tasks, with cost savings per child of £66 (95% CI –93 to 
–39; p<0·0001), £37 (–53 to –20; p<0·0001), and £13 
(–20 to –7; p<0·0001), respectively, in favour of the 
CBT intervention. The appendix summarises results of 
CGI-I Free from primary diagnosis Free from all anxiety diagnoses
Relative risk (95% CI) p value* Relative risk (95% CI) p value* Relative risk (95% CI) p value*
Treatment
GPD-CBT vs SFBT (ref) 1·013 (0·863–1·189) 0·95 1·091 (0·915–1·300) 0·64 1·059 (0·838–1·340) 0·78
Timepoint
After treatment (ref) vs 6 month follow-up 0·883 (0·788–0·990) 0·036 0·773 (0·668–0·894) 0·0014 0·723 (0·601–0·870) 0·0020
Treatment by timepoint interaction 0·964 (0·733–2·125) 0·76 0·873 (0·402–1·437) 0·37 0·923 (0·650–1·955) 0·67
GPD-CBT vs SFBT (ref) after treatment 0·977 (0·782–1·221) 0·83 0·979 (0·733–1·307) 0·88 0·977 (0·690–1·441) 0·98
GPD-CBT vs SFBT (ref) at 6 month follow-up 1·013 (0·863–1·189) 0·87 1·121 (0·930–1·352) 0·23 1·079 (0·842–1·385) 0·54
Sex†
Male vs female 0·794 (0·662–0·951) 0·0093 ·· ·· 0·909 (0·717–1·152) 0·50
Age 1·004 (0·968–1·042) 0·91 1·018 (0·965–1·074) 0·404 0·974 (0·916–1·037) 0·49
CGI-I=Clinician Global Impression-Improvement. GPD-CBT=guided parent-delivered cognitive behavioural therapy. SFBT=solution-focused brief therapy. *p values from 
the fixed effects of the generalised (log-binomial) mixed models. †The fixed effect sex was removed from the model of free from primary diagnosis.
Table 3: Primary analysis results
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cost-utility analyses of the brief guided parent-delivered 
CBT treatment compared with the solution-focused 
brief therapy control for the base-case and the ten 
sensitivity analyses. 
Taking sampling uncertainty into consideration, the 
cost-effectiveness acceptability curve for the base-case 
analysis (figure 2) shows that, in view of the joint 
distribution of incremental mean costs and effects, the 
probability that brief guided parent-delivered CBT is 
cost-effective by comparison with solution-focused brief 
therapy is around 96%, based on UK National Institute 
for Health and Care Excellence thresholds for accepted 
levels of willingness to pay for an extra QALY (usually 
between £20 000 and £30 000). Sensitivity analyses 
supported this finding with the probability of brief 
guided parent-delivered CBT being a cost-effective 
KFQ-c SCAS-c SCAS-p CAIS-c CAIS-p ADIS-c/p CSR
Treatment
GPD-CBT vs SFBT (ref) 0·817 
(–2·785 to 4·418); 
p=0·65
4·944 
(–0·932 to 10·820); 
p=0·098
–2·072 
(–5·733 to 1·590); 
p=0·27
1·129 
(–2·668 to 4·927); 
p=0·56
–0·832 
(–4·008 to 2·344); 
p=0·60
–0·177 
(–0·783 to 0·429); 
p=0·56
Timepoint
After treatment (ref) 
vs 6 month follow–up
2·737  
0·847 to 4·627); 
p=0·0049
5·267 
(2·491 to 8·042); 
p=0·0003
2·939 
(1·078 to 4·798); 
p=0·0022
0·617 
(–1·106 to 2·340); 
p=0·48
1·931 
(0·411 to 3·451); 
p=0·013
0·765 
(0·432 to 1·097); 
p<0·0001
Treatment by timepoint 
interaction
–1·917 
(–5·613 to 1·778); 
p=0·31
3·72 
(–1·596 to 9·053); 
p=0·17
1·99 
(–1·617 to 5·602); 
p=0·28
–1·665 
(–4·963 to 1·632); 
p=0·32
1·839 
(–1·111 to 4·789); 
p=0·22
–0·210 
(–0·860 to 0·440); 
p=0·52
GPD-CBT vs SFBT (ref) 
after treatment
–0·142 
(–3·99 to 3·703); 
p=0·94
6·808 
(0·312 to 13·305); 
p=0·040
–1·705 
(–4·885 to 2·734); 
p=0·57
0·296 
(–3·414 to 4·008); 
p=0·87
0·087 
(–3·521 to 3·696); 
p=0·96
–0·282 
(–0·958 to 0·394); 
p=0·41
GPD-CBT vs SFBT (ref) 
at 6 month follow-up
1·775 
(–2·46 to 6·015); 
p=0·41
3·08 
(–3·33 to 9·487); 
p=0·34
–3·067 
(–7·406 to 1·271); 
p=0·16
1·962 
(–2·568 to 6·493); 
p=0·39
–1·751 
(–5·143 to 1·640); 
p=0·30
–0·072 
(–0·770 to 0·627); 
p=0·84
Child’s baseline endpoint 
score
0·764 
(0·597 to 0·931); 
p<0·0001
0·637 
(0·487 to 0·787); 
p<0·0001
0·602 
(0·478 to 0·726); 
p<0·0001
0·456 
(0·305 to 0·608); 
p=<0·0001
0·724 
(0·570 to 0·878); 
p<0·0001
0·515 
(0·221 to 0·809); 
p=0·0007
Sex
Male (ref) vs female –1·440 
(–5·152 to 2·272); 
p=0·44
–4·340 
(–10·372 to 1·693); 
p=0·16
2·022 
(–1·707 to 5·750); 
p=0·29
–2·587 
(–6·257 to 1·083); 
p=0·17
–0·296 
(–3·527 to 2·934); 
p=0·86
0·118 
(–0·499 to 0·734); 
p=0·71
Age 0·018 
(–1·017 to 1·054); 
p=0·97
0·364 
(–1·628 to 2·355); 
p=0·72
–0·040 
(–1·025 to 0·944); 
p=0·94
–0·132 
(–1·304 to 1·039); 
p=0·82
0·632 
(–0·271 to 1·534); 
p=0·17
–0·141 
(–0·309 to 0·028); 
p=0·1005
Parental level of anxiety p=0·68* p=0·53* p=0·29* p=0·80* p=0·12* p=0·99*
Borderline (ref) vs normal –0·957 
(–5·733 to 3·819); 
p=0·69
–2·340 
(–10·146 to 5·467); 
p=0·55
–3·523 
(–8·334 to 1·288); 
p=0·15
–0·115 
(–5·046 to 4·818); 
p=0·96
–4·135 
(–8·432 to 0·163); 
p=0·059
0·000† 
(–0·820 to 0·820)
Borderline (ref) vs high –3·600 
(–11·715 to 4·516); 
p=0·38
–7·075 
(–19·447 to 5·297); 
p=0·26
–4·980 
(–13·208 to 3·248); 
p=0·23
–2·374 
(–10·162 to 5·414); 
p=0·55
–0·075 
(–8·383 to 8·233); 
p=0·99
0·078 
(–1·319 to 1·475); 
p=0·91
Child’s primary anxiety 
disorder
p=0·54* p=0·92* p=0·023* p=0·55* p=0·077* p=0·063*
GAD (ref) vs SAD –2·844 
(–7·893 to 2·205); 
p=0·27
–2·701 
(–11·151 to 5·749); 
p=0·53
2·549 
(–2·585 to 7·682); 
p=0·33
2·678 
(–2·538 to 7·894); 
p=0·31
3·559 
(–1·109 to 8·226); 
p=0·13
0·488 
(–0·366 to 1·342); 
p=0·26
GAD (ref) vs social phobia 2·384 
(–4·498 to 9·267); 
p=0·49
0·207 
(–13·541 to 13·955); 
p=0·98
–5·200 
(–12·182 to 1·781); 
p=0·14
–3·086 
(–10·375 to 4·203); 
p=0·40
–4·188 
(–10·208 to 1·831); 
p=0·17
–0·794 
(–1·889 to 0·302); 
p=0·15
GAD (ref) vs other 0·698 
(–3·782 to 5·178); 
p=0·76
0·410 
(–6·652 to 7·472); 
p=0·91
–5·770 
(–10·422 to –1·118); 
p=0·016
1·055 
(–3·382 to 5·492); 
0·64
–2·299 
(–6·311 to 1·712); 
p=0·26
–0·676 
(–1·454 to 0·102); 
p=0·088
Data are estimate (95% CI); p value. KFQ-c=Koala Fear Questionnaire-child report. SCAS-c=Spence Children’s Anxiety Scale-child report. SCAS-p=Spence Child Anxiety 
Scale–parent report. CAIS-c=Child Anxiety Impact Scale–child report. CAIS-p=Child Anxiety Impact Scale-parent report. ADIS-c/p=Anxiety Disorders Interview Schedule for 
DSM-IV child and parent version. CSR=Clinical Severity Rating. GPD-CBT=guided parent-delivered cognitive behavioural therapy. SFBT=solution-focused brief therapy. 
GAD=generalised anxiety disorder. SAD=social anxiety disorder. *p values assessing the overall effect of categorical factors with three or more levels do not have a 
corresponding single effect measure so estimates and 95% CIs are not presented. †Final figure as provided by the statistical programme.
Table 4: Secondary analysis results
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alternative to standard practice ranging from 74% 
to 99%.
When brief guided parent-delivered CBT was 
compared with solution-focused brief therapy in terms 
of the societal costs per extra child with a CGI-I outcome 
of much or very much improved (mean difference: effect 
–0·008, 95% CI –0·160 to 0·144; p=0·92; cost: –£448, 
–934 to 37; p=0·070), the cost-effectiveness acceptability 
curve, which accounts for sampling uncertainty, 
indicated that if the NHS and society were willing to pay 
£1000 per extra child with a CGI-I outcome of much or 
very much improved, the probability that brief guided 
parent-delivered CBT would be cost-effective compared 
with solution-focused brief therapy would be 96%, and 
would still be 83% and 57% for a willingness to pay of 
£5000 and £20 000, respectively. However, the maximum 
threshold value that society is willing to pay for an extra 
child with a CGI-I outcome of much or very much 
improved is unknown.
Discussion
Treatment outcomes for children with anxiety 
disorders did not differ significantly according to 
whether they received brief guided parent-delivered 
CBT or solution-focused brief therapy. However, when 
a societal-based cost-effectiveness analysis was done, 
taking sampling uncertainty into account, brief guided 
parent-delivered CBT was likely to represent a cost-
effective use of resources compared with solution-
focused brief therapy. The actual time spent delivering 
treatment was similar between the two treatment 
arms, but cost savings were identified across all 
resource categories in favour of brief guided parent-
delivered CBT, particularly in travel costs because of 
the ability to do phone-based review sessions with 
parents undergoing brief guided parent-delivered CBT. 
The differences in administrative costs were 
unexpected. Further studies are needed to establish 
whether different methods of delivery of these 
two treatments would lead to different cost results.
In view of the brevity of both treatments, that the 
outcomes were similar to those achieved after more 
intensive (child-focused) CBT approaches is notable. For 
example, in the large multicentre Child/Adolescent 
Anxiety Multimodal Study, 60% of children were 
much or very much improved after 14 h-long sessions of 
CBT, and 72% at 6 month follow-up,31 very similar 
to the rates in the present study. Additionally, significant 
improvements were made between the assessments after 
treatment and at 6 months’ follow-up. This finding 
might suggest that if either treatment is adopted as 
part of a stepped-care approach to treatment, it might not 
be necessary to step up all children who do not recover 
immediately, but to allow a period of monitoring 
after treatment. Further investigations are needed 
to help inform decision making about who to step 
up, when, and, indeed, what they should be stepped up to.
A strength of our study is that it took place within a 
routine NHS clinical setting. Despite not restricting 
the study population to children who met formal 
anxiety disorder diagnostic criteria, 90% did meet such 
criteria, and baseline scores on parent-report and child-
report measures were similar to those reported 
in studies with populations with anxiety disorders.8,9 
A development from most previous trials of child-
hood anxiety treatment is that we compared two 
active treatment approaches used routinely by the 
participating therapists.
A further strength of our study is the inclusion of 
a full cost-effectiveness analysis. Notably, the economic 
findings were consistent across various sensitivity 
analyses, and were reinforced when real-world con-
ditions were accounted for, such as larger time 
gaps between treatment sessions and assessments 
(ie, sensitivity analyses 1, 2b, 3b, 7b in the appendix). 
Results based on a restricted health-care provider 
perspective confirmed the main finding, but showed 
that costs associated with childhood anxiety disorders 
would be highly underestimated on this basis (sensitivity 
analyses 7a and 7b), emphasising the importance of 
accounting for all costs borne by society in mental health 
studies. The present study was not powered to detect 
differences in cost, so further trials are warranted to 
validate these findings.
Several limitations should be highlighted. The study 
was powered to detect superiority of one treatment over 
another and did not aim to allow us to comment on their 
equivalence. Attrition from the trial meant that we did 
not achieve the number of participants needed to meet 
our power calculation. Although representative of many 
parts of the UK, as a group, participating families were 
highly educated, affluent, and not ethnically diverse. We 
focused on children aged 5–12 years, yet only one self-
report measure had previously been validated with 
children under the age of 7 years (the Koala Fear 
Questionnaire20), and we therefore relied heavily on 
Figure 2: Cost-effectiveness acceptability curve for brief guided 
parent-delivered cognitive behavioural therapy compared with 
solution-focused brief therapy for the base-case cost-utility analysis
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parent report. Our study did not include a waiting-list 
comparison; however, brief guided parent-delivered CBT 
has previously been shown to produce better outcomes 
than a waiting-list control.8 This finding, together with 
the fact that the outcomes were similar to those from 
other CBT trials, suggests that both interventions were 
effective. Further investigation will be of interest to 
examine the mechanisms by which each treatment has 
its effects. For example, both treatments might have 
ultimately encouraged children to face fears, test beliefs, 
or problem solve effectively.
For the economic analysis, although a high percentage 
of complete data were obtained for treatment resource 
use (98·2–99·8%), missing data for other resource use 
varied from 8·8% to 26·5%, and a quarter of participants 
did not have QALY data at every timepoint. However our 
sensitivity analyses show that the results are consistent 
even in the complete-case scenario. Additionally, this 
study only provides an indication of the short-term cost-
effectiveness of brief guided parent-delivered CBT 
compared with solution-focused brief therapy, and 
future follow-up assessments are warranted to 
determine cost-effectiveness in the longer term. Finally, 
although the costs attributed to school absence for 
children followed methods used in previous studies,29 
focusing mainly on government expenditure per pupil, 
they are likely to underestimate the longer term 
educational disadvantage that children might experience 
as a consequence of mental health difficulties. 
These limitations notwithstanding, although brief 
guided parent-delivered CBT was not clinically superior 
to solution-focused brief therapy, our study provides 
evidence to support its use as a likely cost-effective, brief 
psychological approach for treatment of childhood 
anxiety problems.
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